The Competition Commission of India (CCI) has given its approval for the acquisition of a 1.74 per cent ownership stake in Lenskart Solutions by Kedaara Capital Fund III LLP. Lenskart Solutions specialises in eyewear products, while Kedaara Capital Fund is a registered Alternative Investment Fund (AIF) under SEBI and is part of the Kedaara Group.
In a tweet on Tuesday, CCI confirmed its approval for the acquisition and stated, “CCI approves [the] acquisition of approximately 1.74 per cent equity share capital of Lenskart Solutions Pvt Ltd by Kedaara Capital Fund III LLP (Kedaara Group).”
Additionally, the regulator informed its clearance of the acquisition of a majority share in Indira IVF by Zonnebaars, which is owned by BPEA Private Equity Fund VIII. BPEA Private Equity Fund VIII is an investment fund associated with Sweden-based EQT AB.
Furthermore, CCI has also granted approval for the merger of Spaceway Wellness into Indira IVF. Indira IVF is engaged in providing in vitro fertilisation treatment through its healthcare facilities across India, and Spaceway is one of its promoters.
Earlier this year in July, EQT disclosed that BPEA Private Equity Fund VIII had agreed to acquire a controlling interest in Indira IVF, with TA Associates and the Murdia family retaining a significant minority stake and continuing to lead the company.
These transactions required approval from CCI due to their significance, as the regulator oversees fair business practices and promotes healthy competition in the market.
